Therapeutic targeting of Toll-like receptors in cutaneous disorders

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 12, 2015, Pages 1651-1663

  Matin, Nassim ^a   Tabatabaie, Omidreza ^a   Mohammadinejad, Payam ^a   Rezaei, Nima ^a,b,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSAL SCIENTIFIC EDUCATION AND RESEARCH NETWORK USERN   (Iran)

Author keywords

cutaneous; pattern recognition receptors; skin; therapeutics; Toll like receptors

Indexed keywords

BROPIRIMINE; CPG OLIGODEOXYNUCLEOTIDE; IMIQUIMOD; LOXORIBINE; NICOTINAMIDE; PATTERN RECOGNITION RECEPTOR; PIMECROLIMUS; POLYINOSINIC POLYCYTIDYLIC ACID; RAPAMYCIN; RESIQUIMOD; RETINOIC ACID; TACROLIMUS; TOLL LIKE RECEPTOR; TOSYLCHLORAMIDE SODIUM; ZINC DERIVATIVE; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; BASAL CELL CARCINOMA; CANDIDIASIS; HERPES SIMPLEX; HUMAN; INNATE IMMUNITY; LEISHMANIASIS; LEPROSY; LICHEN PLANUS; NONHUMAN; PEMPHIGUS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; ROSACEA; SARCOIDOSIS; SIGNAL TRANSDUCTION; SKIN CELL; SKIN DISEASE; STAPHYLOCOCCAL SKIN INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; DRUG DESIGN; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; SKIN DISEASES;

ANIMALS; DERMATOLOGIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; SKIN DISEASES; TOLL-LIKE RECEPTORS;

EID: 84951798567     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1069275     Document Type: Review

References (110)

1. Arancibia SA, Beltrán CJ, Aguirre IM, et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007;40(2):97-112
2. Tsan M-F, Gao B. Endogenous ligands of Toll-like receptors. J Leuk Biol 2004;76(3):514-19
3. Ve T, J Gay N, Mansell A, et al. Adaptors in toll-like receptor signaling and their potential as therapeutic targets. Curr Drug Targets 2012;13(11):1360-74
4. Lebre MC, van der Aar AM, van Baarsen L, et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J Invest Dermatol 2006;127(2):331-41
5. Baker B, Ovigne JM, Powles A, et al. Normal keratinocytes express toll-like receptors (TLRs) 1, 2 and 5: modulation of TLR expression in chronic plaque psoriasis. Br J Dermatol 2003;148(4):670-9
6. Renn CN, Sanchez DJ, Ochoa MT, et al. TLR activation of Langerhans celllike dendritic cells triggers an antiviral immune response. J Immunol 2006;177(1):298-305
7. Yu N, Zhang S, Zuo F, et al. Cultured human melanocytes express functional toll-like receptors 2-4, 7 and 9. J Dermatol Sci 2009;56(2):113-20
8. Jin SH, Kang HY. Activation of Toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 2010;22(4):486-9
9. Beylot C, Auffret N, Poli F, et al. Propionibacterium acnes: an update on its role in the pathogenesis of acne. J Eur Acad Dermatol Venereol 2014;28(3):271-8
10. Kim J, Ochoa M-T, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169(3):1535-41
11. Bakry OA, Samaka RM, Sebika H, et al. Toll-like receptor 2 and P. acnes: do they trigger initial acne vulgaris lesions? Anal Quant Cytop Histopathol 2014;36(2):100-10
12. Liu PT, Krutzik SR, Kim J, et al. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005;174(5):2467-70
13. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol 2012;132(9):2198-205
14. Bergler-Czop B, Brzezińska-Wcisło L. Pro-inflammatory cytokines in patients with various kinds of acne treated with isotretinoin. Postepy Dermatol Alergol 2014;31(1):21-8
15. Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol 2007;16(6):500-6
16. Lee YJ, Choi HJ, Kang TW, et al. CBT-SL5, a bacteriocin from Enterococcus faecalis, suppresses the expression of interleukin-8 induced by Propionibacterium acnes in cultured human keratinocytes. J Microbiol Biotechnol 2008;18(7):1308-16
17. Zuliani T, Khammari A, Chaussy H, et al. Ex vivo demonstration of a synergistic effect of Adapalene and benzoyl peroxide on inflammatory acne lesions. Exp Dermatol 2011;20(10):850-3
18. Jarrousse V, Castex-Rizzi N, Khammari A, et al. Zinc salts inhibit in vitro Toll-like receptor 2 surface expression by keratinocytes. Eur J Dermatol 2007;17(6):492-6
19. Grange PA, Raingeaud J, Calvez V, et al. Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kB and MAPK pathways. J Dermatol Sci 2009;56(2):106-12
20. Netea MG, Brown GD, Kullberg BJ, et al. An integrated model of the recognition of Candida albicans by the innate immune system. Nat Rev Microbiol 2008;6(1):67-78
21. Netea MG, Van der Meer JW, Kullberg BJ. Recognition of fungal pathogens by Toll-like receptors. Immunol Fungal Inf 2007;259-72
22. Kasperkovitz PV, Khan NS, Tam JM, et al. Toll-like receptor 9 modulates macrophage antifungal effector function during innate recognition of Candida albicans and Saccharomyces cerevisiae. Infec Imm 2011;79(12):4858-67
23. Kasperkovitz PV, Cardenas ML, Vyas JM. TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking. J Immunol 2010;185(12):7614-22
24. Razonable RR, Henault M, Lee LN, et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by coactivation of toll-like receptors 1 and 2. Antim Agents Chemother 2005;49(4):1617-21
25. Sau K, Mambula SS, Latz E, et al. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Tolllike receptor- and CD14-dependent mechanism. J Biol Chem 2003;278(39):37561-8
26. Moretti S, Bozza S, Massi-Benedetti C, et al. An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicro Chemother 2014;69(4):1065-74
27. Salvenmoser S, Seidler MJ, Dalpke A, et al. Effects of caspofungin, Candida albicans and Aspergillus fumigatus on toll-like receptor 9 of GM-CSF-stimulated PMNs. FEMS Immu Med Microbiol 2010;60(1):74-7
28. Mihu MR, Pattabhi R, Nosanchuk JD. The impact of antifungals on toll-like receptors. Front Microbiol 2014;5:99
29. Rizzo A, Losacco A, Carratelli CR. Lactobacillus crispatus modulates epithelial cell defense against Candida albicans through Toll-like receptors 2 and 4, interleukin 8 and human bdefensins 2 and 3. Immunol Lett 2013;156(1):102-9
30. Décanis N, Savignac K, Rouabhia M. Farnesol promotes epithelial cell defense against Candida albicans through Toll-like receptor 2 expression, interleukin-6 and human β-defensin 2 production. Cytokine 2009;45(2):132-40
31. Ma Y, He B. Recognition of herpes simplex viruses: toll-like receptors and Beyond. J Mol Biol 2014;426(6):1133-47
32. McGowin CL, Pyles RB. Mucosal treatments for herpes simplex virus: insights on targeted immunoprophylaxis and therapy. Fut Microbiol 2010;5(1):15-22
33. Tuon FF, Fernandes ER, Duarte MI, et al. The expression of TLR2, TLR4 and TLR9 in the epidermis of patients with cutaneous leishmaniasis. J Dermatol Sci 2010;59(1):55-7
34. Mukherjee AK, Gupta G, Adhikari A, et al. Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: Role of TLR4 and TLR9. Int Immunopharmacol 2012;12(4):565-72
35. Sane SA, Shakya N, Haq W, et al. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis. J Antimicro Chemother 2010;65(7):1448-54
36. Gupta S, Sane SA, Shakya N, et al. CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis. Antim Agents Chemother 2011;55(7):3461-4
37. Wu W, Weigand L, Belkaid Y, et al. Immunomodulatory effects associated with a live vaccine against Leishmania major containing CpG oligodeoxynucleotides. Eur J Immunol 2006;36(12):3238-47
38. Huang L, Hinchman M, Mendez S. Coinjection with TLR2 Agonist Pam3CSK4 Reduces the Pathology of Leishmanization in Mice. PLoS Neg Trop Dis 2015;9(3):e0003546-e46
39. Wong SH, Gochhait S, Malhotra D, et al. Leprosy and the adaptation of human toll-like receptor 1. PLoS Path 2010;6(7):e1000979
40. Bochud PY, Sinsimer D, Aderem A, et al. Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. Eur J Clin Microbiol Infect Dis 2009;28(9):1055-65
41. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Tolllike receptors 2 and 1 in human leprosy. Nat Med 2003;9(5):525-32
42. Hilmi D, Parcina M, Stollewerk D, et al. Heterogeneity of host TLR2 stimulation by Staphylocoocus aureus isolates. PLoS One 2014;9(5):e96416
43. Bishayi B, Bandyopadhyay D, Majhi A, et al. Possible role of toll-like receptor-2 in the intracellular survival of Staphylococcus aureus in murine peritoneal macrophages: involvement of cytokines and anti-oxidant enzymes. Scand J Immunol 2014;80(2):127-43
44. Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2010;131(3):688-97
45. Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013;69(4):570-7
46. Potaczek D, Nastalek M, Okumura K, et al. An association of TLR2-16934A> T polymorphism and severity/phenotype of atopic dermatitis. J Eur Acad Dermatol Venereol 2011;25(6):715-21
47. Kaesler S, Volz T, Skabytska Y, et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10. J All Clin Immunol 2014;134(1):92-9
48. Lesiak A, Smolewski P, Sobolewska-Sztychny D, et al. The role of T-regulatory cells and toll-like receptors 2 and 4 in atopic dermatitis. Scand J Immunol 2012;76(4):405-10
49. Kuo I-H, Carpenter-Mendini A, Yoshida T, et al. Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Invest Dermatol 2012;133(4):988-98
50. Antiga E, Volpi W, Torchia D, et al. Effects of tacrolimus ointment on Tolllike receptors in atopic dermatitis. Clin Exper Dermatol 2011;36(3):235-41
51. Begon É, Michel L, Flageul B, et al. Expression, subcellular localization and cytokinic modulation of Toll-like receptors (TLRs) in normal human keratinocytes: TLR2 up-regulation in psoriatic skin. Eur J Dermatol 2007;17(6):497-506
52. Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol 2013;43(12):3138-46
53. Patel U, Mark N, Machler B, et al. Imiquimod 5% cream induced psoriasis: a case report, summary of the literature and mechanism. Br J Dermatol 2011;164(3):670-2
54. Jiang W, Zhu F-G, Bhagat L, et al. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol 2013;133(7):1777-84
55. Suarez-Farinas M, Belasco J, Sullivan T, et al. Treatment of psoriasis patients with IMO-3100 shows improvement in gene expression patterns of meta-analysis derived-3 transcriptome and IL-17 pathway arthritis and rheumatism. Wiley-Blackwell; Hoboken, NJ USA: 2013. p. S495-S95
56. Janardhanam SB, Prakasam S, Swaminathan VT, et al. Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus. Arch Oral Biol 2012;57(5):495-502
57. Siponen M, Kauppila JH, Soini Y, et al. TLR4 and TLR9 are induced in oral lichen planus. J Oral Pathol Med 2012;41(10):741-7
58. Salem SAM, Abu-Zeid RM, Nada OH. Immunohistochemical study of toll-like receptors 1 and 2 expression in cutaneous lichen planus lesions. Arch Dermatol Res 2013;305(2):125-31
59. Domingues R, Carvalho GC, Silva Oliveira L, et al. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus. Br J Dermatol 2015;172(1):48-55
60. Abida O, Krichen-Makni S, Kharrat N, et al. Potential Role of TLR ligand in aethiopathogenesis of Tunisian endemic pemphigus foliaceus. Biochem Physiol 2013;2(3):117
61. Sebaratnam D, Martin L, Rubin A, et al. Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for pemphigus. Clin Exp Dermatol 2011;36(1):91-3
62. Celhar T, Magalhaes R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol Res 2012;53(1-3):58-77
63. Yokogawa M, Takaishi M, Nakajima K, et al. Epicutaneous application of tolllike receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic lupus erythematosus. Arth Rheumatol 2014;66(3):694-706
64. Huizenga T, Kado J, Mehregan DR, et al. Identifying Toll-like Receptor Expression in Cutaneous Sarcoidosis. Am J Dermatopathol 2015;37(1):67-72
65. Agarwal SK, Wu M, Livingston CK, et al. Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts. Arth Res Ther 2011;13(1):R3
66. Farina GA, York MR, Di Marzio M, et al. Poly (I: C) drives type I IFN- and TGFb-mediated inflammation and dermal fibrosis simulating altered gene expression in systemic sclerosis. J Invest Dermatol 2010;130(11):2583-93
67. Holldack J. Toll-like receptors as therapeutic targets for cancer. Drug Discov Today 2014;19(4):379-82
68. Weng H, Deng Y, Xie Y, et al. Expression and significance of HMGB1, TLR4 and NF-kappaB p65 in human epidermal tumors. BMC Cancer 2013;13(1):311
69. Muehleisen B, Jiang SB, Gladsjo JA, et al. Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patients. PLoS One 2012;7(7):e40754
70. Vidal D, Matías-Guiu X, Alomar A. Open study of the efficacy and mechanism of action of topical imiquimod in basal cell carcinoma. Clin Exp Dermatol 2004;29(5):518-25
71. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Sur 2006;32(1):63-9
72. Rigel DS, Torres AM, Ely H. Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. J Drugs Dermatol 2008;7(1 Suppl 1):s15-16
73. Tillman D Jr, Carroll M. A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. J Drugs Dermatol 2008;7(1 Suppl 1):s7-14
74. Ezughah FI, Affleck AG, Evans A, et al. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. J Dermatol Treat 2008;19(3):156-8
75. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008;18(6):677-82
76. Daudén E. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice. J Eur Acad Dermatol Venereol 2011;25(11):1304-10
77. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ. Study protocol The SINS trial: A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials 2010;11:42
78. Bath-Hextall F, Ozolins M, Armstrong SJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol 2014;15(1):96-105
79. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, doubleblind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50(5):714-21
80. Torres A, Storey L, Anders M, et al. Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream. J Transl Med 2007;5(1):7
81. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008;159(1):205-10
82. Burns EM, Yusuf N. Toll-like receptors and skin cancer. Front Immunol 2014;5
83. Saint-Jean M, Knol AC, Nguyen JM, et al. TLR expression in human melanoma cells. Eur J Dermatol 2012;21(6):899-905
84. Mittal D, Saccheri F, Vénéreau E, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010;29(13):2242-52
85. Singh M, Khong H, Dai Z, et al. Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation. J Immunol 2014;193(9):4722-31
86. Millward M, Underhill C, Lobb S, et al. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 2013;108(10):1998-2004
87. Green D, Dalgleish A, Belonwu N, et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol 2008;159(3):606-14
88. Buettiker UV, Yawalkar NY, Braathen LR, et al. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. Arch Dermatol 2008;144(7):943-5
89. Smith KJ, Hamza S, Skelton H. The imidazoquinolines and their place in the therapy of cutaneous disease. Expert Opin Pharmacother 2003;4(7):1105-19
90. David CV, Nguyen H, Goldenberg G. Imiquimod: a review of off-label clinical applications. J Drugs Dermatol 2011;10(11):1300-6
91. Astry C, Birmachu W, Harrison LI, et al. Cutaneous Pharmacodynamics of a Toll-Like Receptor 7 Agonist, 852A, in Humans. J Clin Pharmacol 2008;48(6):755-62
92. Valins W, Amini S, Berman B. The expression of toll-like receptors in dermatological diseases and the therapeutic effect of current and newer topical toll-like receptor modulators. J Clin Aesth Dermatol 2010;3(9):20
93. Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications to dermatologic disease. J Am Acad Dermatol 2006;54(6):951-83
94. Ermertcan A, Öztürk F, Gündüz K. Toll-like receptors and skin. J Eur Acad Dermatol Venereol 2011;25(9):997-1006
95. Büchau AS, Schauber J, Hultsch T, et al. Pimecrolimus enhances TLR2/6-induced expression of antimicrobial peptides in keratinocytes. J Invest Dermatol 2008;128(11):2646-54
96. Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transpl 2010;10(6):1385-93
97. Yamamoto M, Sato T, Beren J, et al. The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides. Biomaterials 2011;32(18):4238-42
98. Molenkamp BG, Sluijter BJ, van Leeuwen PA, et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008;14(14):4532-42
99. Borkowski AW, Kuo I-H, Bernard JJ, et al. Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage. J Invest Dermatol 2015;135(2):569-78
100. Kim CH, Do Park C, Lee AY. Administration of poly (I: C) improved dermatophagoides farinae-induced atopic dermatitis-like skin lesions in NC/Nga mice by the regulation of Th1/Th2 balance. Vaccine 2012;30(14):2405-10
101. Salaun B, Lebecque S, Matikainen S, et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 2007;13(15):4565-74
102. Phase I, Phase I. open label study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without montanide® ISA-51 VG in patients with high risk melanoma in complete clinical remission. ClinicalTrials.gov Identifier: NCT01079741. 2010
103. Szabo A, Osman RM, Bacskai I, et al. Temporally designed treatment of melanoma cells by ATRA and polyI: C results in enhanced chemokine and IFNb secretion controlled differently by TLR3 and MDA5. Melan Res 2012;22(5):351-61
104. Ofodile ON. Disifin (sodium tosylchloramide) and Toll-like receptors (TLRs): evolving importance in health and diseases. J Indust Micro Biotechnol 2007;34(12):751-62
105. Hernández-Sancén P, Maldonado-Bernal C. Relevance of single-nucleotide polymorphisms in human TLR genes to infectious and inflammatory diseases and cancer. Genes Immun 2014;15(4):199-209
106. Grillo-Ardila CF, Angel-Müller E, Salazar-Díaz LC, et al. Imiquimod for anogenital warts in nonimmunocompromised adults. Cochrane Library 2014;11:CD010389
107. Terhorst D, Kalali BN, Ollert M, et al. The role of toll-like receptors in host defenses and their relevance to dermatologic diseases. Am J Clin Dermatol 2010;11(1):1-10
108. Hofmann U, Ertl G, Frantz S. Toll-like receptors as potential therapeutic targets in cardiac dysfunction. Expert Opin Therap Targets 2011;15(6):753-65
109. Watanabe Y, Nagai Y, Takatsu K. Activation and regulation of the pattern recognition receptors in obesity-induced adipose tissue inflammation and insulin resistance. Nutrients 2013;5(9):3757-78
110. Dummer R, Hauschild A, Becker JC, et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res 2008;14(3):856-64